BR112016000335A2 - método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica - Google Patents

método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica

Info

Publication number
BR112016000335A2
BR112016000335A2 BR112016000335A BR112016000335A BR112016000335A2 BR 112016000335 A2 BR112016000335 A2 BR 112016000335A2 BR 112016000335 A BR112016000335 A BR 112016000335A BR 112016000335 A BR112016000335 A BR 112016000335A BR 112016000335 A2 BR112016000335 A2 BR 112016000335A2
Authority
BR
Brazil
Prior art keywords
treating
papulopustular rosacea
pharmaceutical composition
inflammatory lesions
rosacea
Prior art date
Application number
BR112016000335A
Other languages
English (en)
Other versions
BR112016000335A8 (pt
Inventor
Jean Jacovella
Jean-Paul Chappuis
Laurence Salin
Philippe Briantais
Alexandre Kaoukhov
Michael Graeber
Michel Poncet
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52133217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016000335(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of BR112016000335A2 publication Critical patent/BR112016000335A2/pt
Publication of BR112016000335A8 publication Critical patent/BR112016000335A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J9/00—Feeding-bottles in general
    • A61J9/06—Holders for bottles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112016000335A 2013-07-08 2014-07-08 método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica BR112016000335A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843540P 2013-07-08 2013-07-08
US201361919208P 2013-12-20 2013-12-20
US201461927717P 2014-01-15 2014-01-15
US14/209,958 US9233118B2 (en) 2013-07-08 2014-03-13 Treatment of papulopustular rosacea with ivermectin
PCT/US2014/045739 WO2015006319A1 (en) 2013-07-08 2014-07-08 Treatment of papulopustular rosacea with ivermectin

Publications (2)

Publication Number Publication Date
BR112016000335A2 true BR112016000335A2 (pt) 2017-07-25
BR112016000335A8 BR112016000335A8 (pt) 2020-01-07

Family

ID=52133217

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112016000350A BR112016000350A8 (pt) 2013-07-08 2014-07-08 métodos de tratamento de lesões inflamatórias da rosácea e usos de uma composição farmacêutica
BR112016000335A BR112016000335A8 (pt) 2013-07-08 2014-07-08 método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112016000350A BR112016000350A8 (pt) 2013-07-08 2014-07-08 métodos de tratamento de lesões inflamatórias da rosácea e usos de uma composição farmacêutica

Country Status (17)

Country Link
US (12) US9233118B2 (pt)
EP (2) EP3019174A1 (pt)
JP (7) JP6438466B2 (pt)
KR (2) KR101864799B1 (pt)
CN (4) CN111467301A (pt)
AU (2) AU2014287408B2 (pt)
BR (2) BR112016000350A8 (pt)
CA (2) CA2916704C (pt)
CL (2) CL2016000009A1 (pt)
HK (2) HK1223841A1 (pt)
IL (3) IL243315B (pt)
MX (2) MX2016000122A (pt)
NZ (2) NZ716033A (pt)
RU (2) RU2633481C2 (pt)
SG (2) SG11201510635PA (pt)
WO (2) WO2015006305A1 (pt)
ZA (1) ZA201600358B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3074021B1 (en) 2013-11-29 2021-05-12 Galderma SA Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis
FR3032616B1 (fr) * 2015-02-12 2017-02-24 Galderma Sa Compose de la famille des avermectines pour le traitement et/ou la prevention des folliculites
WO2017085226A1 (en) * 2015-11-17 2017-05-26 Galderma Sa Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea
BR112019002213A2 (pt) * 2016-08-04 2019-05-14 Nestlé Skin Health Sa composições e o uso das mesmas para tratar ou prevenir rosácea
CN106397233A (zh) * 2016-08-26 2017-02-15 南通奥凯生物技术开发有限公司 一种医药级乙二胺四乙酸二钠的制备方法
WO2018060870A1 (en) * 2016-09-30 2018-04-05 Aurobindo Pharma Limited Pharmaceutical composition of ivermectin and process for preparation thereof
BR112020012018A2 (pt) 2017-12-15 2020-11-24 Tarsus Pharmaceuticals, Inc. formulações de parasiticida de isoxazolina e métodos para tratar blefarite
JP7129005B2 (ja) * 2018-09-28 2022-09-01 Toto株式会社 水洗大便器
WO2020172101A1 (en) 2019-02-18 2020-08-27 Mary Kay Inc. Topical skin compositions for treating rosacea and skin redness
CN111728959B (zh) * 2020-08-11 2023-02-03 黑龙江天龙药业有限公司 一种抑制油脂分泌且清螨虫的鼻膜贴及其制备方法
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations
WO2022269665A1 (ja) * 2021-06-21 2022-12-29 マルホ株式会社 外用剤
KR102346125B1 (ko) 2021-10-15 2022-01-03 (주)나비바이오텍 이버멕틴 정성 검사용 래피드 키트

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA06863A (fr) 1980-08-04 1983-02-28 Merck & Co Inc Solubilisation de l'invermectine dans l'eau.
US5332577A (en) 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5656280A (en) 1994-12-06 1997-08-12 Helene Curtis, Inc. Water-in-oil-in-water compositions
FR2754452B1 (fr) 1996-10-11 2003-02-14 Oreal Emulsion h/e a forte teneur en electrolytes et leur utilisation en dermo-cosmetique, notamment pour traiter les phenomenes d'irritation et/ou de peaux sensibles
US5952372A (en) 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
FR2787322B1 (fr) 1998-12-18 2002-10-18 Galderma Res & Dev Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie
US6133310A (en) 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6399652B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
US6399651B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
US6319945B1 (en) 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
DE10063946A1 (de) 2000-12-20 2002-07-04 Basf Ag Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
WO2003066009A1 (en) 2002-02-08 2003-08-14 Merck & Co., Inc. Topical ivermectin composition
CN1649578A (zh) 2002-03-04 2005-08-03 戴弗根斯公司 杀线虫的脂肪酸和脂肪酸酯相关化合物
RU2350333C3 (ru) * 2003-04-24 2018-08-24 Галдерма С.А. Применение ивермектина для лечения дерматологических расстройств
FR2854074B1 (fr) * 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
EP1600158A1 (en) 2004-05-26 2005-11-30 Galderma Research & Development, S.N.C. Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
FR2883181B1 (fr) 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886852B1 (fr) 2005-06-10 2007-11-23 Galderma Sa Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2886850B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2886851B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2894823B1 (fr) 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) 2006-09-28 2012-09-21 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2907012B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
FR2907013B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations
US20120004200A1 (en) 2008-12-23 2012-01-05 Galderma S.A. Topical pharmaceutical composition containing a water-sensitive active principle
EP2391208A4 (en) 2009-01-30 2012-09-12 Yissum Res Dev Co COMPOSITIONS FOR THE TREATMENT OF NAILS AND SKIN
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee

Also Published As

Publication number Publication date
KR101863085B1 (ko) 2018-06-01
BR112016000350A8 (pt) 2020-01-07
US9233118B2 (en) 2016-01-12
MX2016000122A (es) 2016-06-15
RU2633076C2 (ru) 2017-10-11
CA2916668A1 (en) 2015-01-15
US20150011489A1 (en) 2015-01-08
US10206939B2 (en) 2019-02-19
RU2016103715A (ru) 2017-08-11
US20180207188A1 (en) 2018-07-26
EP3019174A1 (en) 2016-05-18
CN111494399A (zh) 2020-08-07
JP2016526572A (ja) 2016-09-05
WO2015006319A1 (en) 2015-01-15
NZ716034A (en) 2017-01-27
IL243314A0 (en) 2016-02-29
US20220347198A1 (en) 2022-11-03
IL243315A0 (en) 2016-02-29
JP6438466B2 (ja) 2018-12-12
IL274058B (en) 2022-02-01
WO2015006305A1 (en) 2015-01-15
ZA201600358B (en) 2019-11-27
CA2916704C (en) 2018-11-20
JP2017197562A (ja) 2017-11-02
RU2016103753A (ru) 2017-08-11
US20200000835A1 (en) 2020-01-02
CN105792829A (zh) 2016-07-20
CN111467301A (zh) 2020-07-31
BR112016000335A8 (pt) 2020-01-07
US9233117B2 (en) 2016-01-12
KR20160061311A (ko) 2016-05-31
CN105828825A (zh) 2016-08-03
US20160175337A1 (en) 2016-06-23
JP2019073527A (ja) 2019-05-16
KR20160061310A (ko) 2016-05-31
RU2633481C2 (ru) 2017-10-12
AU2014287422A1 (en) 2016-02-11
US20180177813A1 (en) 2018-06-28
US20180264021A1 (en) 2018-09-20
JP2018184437A (ja) 2018-11-22
IL274058A (en) 2020-06-30
SG11201510635PA (en) 2016-01-28
NZ716033A (en) 2017-01-27
JP6653734B2 (ja) 2020-02-26
JP2016523968A (ja) 2016-08-12
US20150011490A1 (en) 2015-01-08
US20150011491A1 (en) 2015-01-08
EP3019173A1 (en) 2016-05-18
SG11201510420UA (en) 2016-01-28
CL2016000009A1 (es) 2016-08-19
AU2014287422B2 (en) 2017-04-13
KR101864799B1 (ko) 2018-06-05
US9089587B2 (en) 2015-07-28
AU2014287408A1 (en) 2016-02-11
AU2014287408B2 (en) 2017-05-04
IL243315B (en) 2022-02-01
JP2021059590A (ja) 2021-04-15
JP2023052490A (ja) 2023-04-11
HK1223841A1 (zh) 2017-08-11
CA2916704A1 (en) 2015-01-15
BR112016000350A2 (pt) 2017-07-25
HK1223842A1 (zh) 2017-08-11
MX2016000121A (es) 2016-07-14
US20160184342A1 (en) 2016-06-30
US20210177882A1 (en) 2021-06-17
CL2016000008A1 (es) 2016-08-05
US20160143935A1 (en) 2016-05-26
IL243314B (en) 2022-02-01

Similar Documents

Publication Publication Date Title
BR112016000335A2 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
FR21C1059I2 (fr) Compositions pharmaceutiques
BR112015031475A2 (pt) composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
BR112016011684A2 (pt) método, e composição de cimento
BR112016011830A2 (pt) composições bacterianas sinergísticas e métodos para produção e uso das mesmas.
FI20135175A (fi) Aktuaattori ja menetelmä aktuaattorin parantamiseksi
CL2015002754A1 (es) Método para descelularización de injertos de tejido
BR112015023310A2 (pt) composições, métodos e kits para redução de níveis lipídicos
BR112015028115A2 (pt) métodos e composições para o tratamento de câncer
BR112016021034A2 (pt) Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit
HK1210806A1 (en) Method for manufacturing immunocyte-containing composition, and cancer-treating composition
BR112015022347A2 (pt) composição para vacinação, método para produzir uma composição para vacinação e uso de composição
EP3066472A4 (en) Compositions and methods for detecting and/or treating inflammation
EP2968194A4 (en) DOXYCYCLINE FORMULATIONS AND METHODS FOR TREATING ROSACEAE
SMT201500214B (it) Nuova composizione farmaceutica per il trattamentodi infezioni fungine
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
DK3275452T3 (da) Farmaceutisk sammensætning med silibinin
FR3001392B1 (fr) Composition dermatologique amelioree
FR3002452B1 (fr) Composition dermatologique antimicrobienne topique
BR112015005627A2 (pt) composto, composição farmacêutica, uso de composto, método de tratamento e invenção.
FI20135780A (fi) Menetelmä ja laite kehon koostumuksen määrittämiseksi
EP3078659A4 (en) 3-FURYL-2-CYANO-2-ACRYLAMIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF
DK3003401T3 (da) Farmaceutisk præparat

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]